risedronic acid has been researched along with candesartan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cheung, P; Harrison, SD; McMurry, AS; Meshaw, KR; Rainbolt, EA; Roix, JJ; Saha, S | 1 |
1 review(s) available for risedronic acid and candesartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for risedronic acid and candesartan
| Article | Year |
|---|---|
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; Drug Approval; Drug Repositioning; Etidronic Acid; Female; High-Throughput Screening Assays; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasms; Risedronic Acid; Temozolomide; Tetrazoles; Xenograft Model Antitumor Assays | 2014 |